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Abstract 
PIN1 is a peptidyl-prolyl cis/trans  isomerase that 
binds and catalyses isomerization of the specific motif 
comprising a phosphorylated serine or threonine residue 
preceding a proline (pSer/Thr-Pro) in proteins. PIN1 
can therefore induce conformational and functional 
changes of its interacting proteins that are regulated 
by proline-directed serine/threonine phosphorylation. 
Through this phosphorylation-dependent prolyl 
isomerization, PIN1 fine-tunes the functions of key 
phosphoproteins (e.g. , cyclin D1, survivin, β-catenin 
and x-protein of hepatitis B virus) that are involved 
in the regulation of cell cycle progression, apoptosis, 
proliferation and oncogenic transformation. PIN1 has 
been found to be over-expressed in many cancers, 
including human hepatocellular carcinoma (HCC). 
It has been shown previously that overexpression 
of PIN1 contributes to the development of HCC in-
vitro  and in xenograft mouse model. In this review, 
we first discussed the aberrant transcription factor 
expression, miRNAs dysregulation, PIN1 gene promoter 
polymorphisms and phosphorylation of PIN1 as 
potential mechanisms underlying PIN1 overexpression 
in cancers. Furthermore, we also examined the role 
of PIN1 in HCC tumourigenesis by reviewing the 
interactions between PIN1 and various cellular and viral 
proteins that are involved in β-catenin, NOTCH, and 
PI3K/Akt/mTOR pathways, apoptosis, angiogenesis and 
epithelial-mesenchymal transition. Finally, the potential 
of PIN1 inhibitors as an anti-cancer therapy was 
explored and discussed. 
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Core tip: PIN1 specifically binds and catalyses iso-
merization of the pSer/Thr-Pro motif of target pro-
teins, thereby modulating their functions. Many PIN1-
interacting proteins are involved in cellular transformation 
and maintenance of malignant phenotype, and 
overexpression of PIN1 is frequently found in various 
cancer types, including hepatocellular carcinoma (HCC). 
Through interacting with regulatory proteins of key 
signalling pathways, such as β-catenin, cyclin D1, and 
HBx, PIN1 drives and amplifies the oncogenic signals 
essential for the development of HCC. Given its diverse 
oncogenic functions in hepatocarcinogenesis, PIN1 
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represents a potential therapeutic target in the treatment 
of HCC. 
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth leading 
cancer in men and the ninth for women worldwide, 
with estimated 782000 new cases in 2012. It is 
one of the most common causes of cancer death, 
leading to 746000 deaths annually[1]. Chronic 
infection with hepatitis B virus (HBV) or hepatitis C 
virus (HCV) is the major risk factor[2], accounting 
for 92% and 43% of HCC cases in developing and 
developed countries, respectively. HCC is an aggressive 
malignant tumour associated with a poor prognosis, 
and only a small proportion of HCCs is detected at 
an early stage. Early-stage HCCs are amenable to 
potentially curative treatments, such as surgical 
resection, liver transplantation, transcatheter arterial 
chemoembolization (TACE) and radiofrequency ablation 
(RFA)[3]. Nonetheless, HCCs are frequently diagnosed 
at advanced-stage and patients with advanced HCCs 
are not candidates for curative therapies. Conventional 
chemotherapy is ineffective for advanced HCCs 
because of the development of chemo-resistance 
and early occurrence of metastasis[4-6]. A thorough 
understanding of the pathogenesis and biology of HCC 
provides the mechanistic basis for designing effective 
HCC therapies.
Protein phosphorylation is a post-translational 
modification that plays an important role in the regu­
lation of signalling pathways. Through activation of 
multiple protein kinases, such as cyclin dependent 
kinases (CDKs) and mitogen activated protein kinases 
(MAPKs), phosphorylation of proteins in serine or 
threonine residues preceding proline (pSer/ Thr-Pro) 
motif has been linked to dysregulated cell proliferation 
and malignant transformation[7,8]. The identification 
of peptidyl-prolyl cis/trans isomerase PIN1 provides a 
new post-phosphorylation regulatory mechanism in cell 
signalling[9-12]. PIN1 is a small and highly evolutionarily 
conserved 18-kDa protein, and is mainly localized 
in the nucleus[11,13,14]. It binds specific pSer/Thr-Pro 
motif in certain proteins through its amino-terminal 
WW domain, and isomerizes the pSer/Thr-Pro peptide 
bonds with its carboxyl-terminal prolyl isomerase 
(PPIase) domain[7,11,15] (Figure 1). PIN1-catalysed 
isomerization induces conformational changes of 
its target proteins, resulting in alterations of their 
enzymatic activities, phosphorylation status, protein-
protein interaction patterns, subcellular localization, 
and protein stability. Conceivably, PIN1 plays an 
important role in diverse cellular processes, including 
cell cycle progression, differentiation, apoptosis and 
proliferation, as well as transformation[11,16-19]. Indeed, 
many PIN1-interacting partners, such as β-catenin, 
c-Jun, cyclin D1, cyclin E, Myc, nuclear factor-kappa B 
(NF-κB)-p65, p53 and p73, are important in regulating 
cell cycle progression and cell proliferation, and are 
often dysregulated in cancer[17,18,20-25]. Thus, the 
role of PIN1 in enhancing the oncogenic potential of 
these proteins via phosphorylation-dependent prolyl 
isomerization is important during cancer development.
In this article, we discuss the possible mechanisms 
underlying dysregulated PIN1 expression in cancer, the 
oncogenic roles of PIN1 in hepatocarcinogenesis, and 
the potential of PIN1 inhibitors as anti-cancer agents. 
REGULATION OF PIN1 EXPRESSION AND 
ACTIVITY
In normal cells, PIN1 expression is usually very low 
and is tightly regulated by the retinoblastoma protein 
(Rb)-E2F pathway[26,27]. The binding between Rb and 
E2F proteins is controlled by the phosphorylation of 
Rb. Hypophosphorylated Rb binds E2F transcription 
factors and inhibits its transcriptional activity towards 
the PIN1 gene. In response to cell proliferative stimuli, 
CDK-cyclin complexes phosphorylate and inactivate Rb 
to release E2F. In turn, E2F binds to the E2F-binding 
sites of the PIN1 promoter and directly activates 
transcription of the PIN1 gene. Interestingly, PIN1 has 
also been found to interact with Rb and enhance its 
hyperphosphorylation[28,29]. Therefore, PIN1 inactivates 
Rb and promotes E2F target gene activation. Since 
dysregulation of the Rb-E2F pathway is frequently 
found in various cancers[30], it is speculated that 
abnormalities of this pathway may contribute to PIN1 
overexpression in cancers. Furthermore, PIN1 interacts 
with phosphorylated NOTCH1 to enhance NOTCH1 
transcriptional activity, which in turn, increases the 
transcription of PIN1, resulting in a positive feedback 
loop for PIN1 overexpression in cancers[31]. In addition 
to E2F and NOTCH1, forkhead box transcription factor 
FOXC1 also enhances PIN1 promoter activity, resulting 
in increased mRNA and protein expression of PIN1 in 
breast cancer cells[32].
MicroRNAs (miRNAs) are small non-coding RNA 
that functions as a negative regulator of gene ex-
pression by binding to the 3′UTR of target mRNA to 
inhibit gene expression at the post-transcriptional 
level[33]. Dysregulation of miRNAs expression is 
frequently observed in cancers[34]. In HCC, a global 
reduction of miRNAs expression is associated with HCC 
progression[35], suggesting that most of the expressed 
miRNAs in normal hepatocytes function as tumour 
suppressors. Some of these miRNAs may target the 
expression of PIN1 and their reduced expression may 
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therefore result in the PIN1 overexpression observed 
in HCC. Currently, three miRNAs have been shown to 
negatively regulate PIN1 expression in cancers. miR-
200b/c and miR-296-5p directly target and suppress 
PIN1 expression in breast cancer and prostate cancer 
cells, respectively[36-38]. However, no specific miRNA 
has been reported to target PIN1 expression in HCC.
Single nucleotide polymorphism (SNP) of the PIN1 
gene promoter may also contribute to the regulation 
of PIN1 expression. The promoter region of PIN1 
gene contains two SNPs [rs2233678 (-842G/C) and 
rs2233679 (-667C/T)] and one synonymous SNP 
[rs2233682 (Gln33GlnG>A)] in exon 2. Genotype 
-842CC is associated with lower PIN1 protein ex-
pression in peripheral mononuclear cells, whereas 
­677C/T genotype does not have significant effect on 
PIN1 expression[39]. Similar result was also found in 
squamous cell carcinoma of head and neck (SCCHN), 
with -842C genotype but not -677C/T associated with 
a lower PIN1 promoter activity and a lower risk of 
SCCHN[40].
In addition to the transcriptional regulation, PIN1 
level is also regulated through post-translational 
modification. Phosphorylation at Ser65 by Polo-like 
kinase I (PLK1) inhibits ubiquitination of PIN1, resulting 
in decreased proteasomal degradation and increased 
protein level[41]. Moreover, multiple regulators have 
also been found to modulate the activity of PIN1 
by post-translational modifications. Sumoylation 
of Lys6 on the WW domain and Lys63 on the PPIase 
domain suppress PIN1 protein-binding and catalytic 
abilities, respectively. De-sumoylation on those sites 
by SUMO1/sentrin specific peptidase 1 (SENP1) 
reverses the inhibitory function on PIN1 and increases 
PIN1 stability[42]. In addition, mixed-lineage kinase 
3-induced phosphorylation of PIN1 at Ser138 enhances 
PIN1 catalytic activity[43], whereas death-associated 
protein kinase 1-induced phosphorylation of PIN1 at 
Ser71 abolishes PIN1 catalytic activity[14]. Furthermore, 
protein kinase A, ribosomal S6 kinase 2 and Aurora 
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Figure 1  Structure of peptidyl-prolyl-isomerase PIN1 protein. Ribbon diagrams of (A) PIN1 (NCBI Structure No. 1NMV), (B) WW binding domain (NCBI Structure 
No. 1I8H), and (C) PPIase catalytic domain (NCBI Structure No. 1NMW) were drawn with the Swiss-Pdb Viewer[11,15,115,116]. α-helices and β-strands are denoted by 
coils and arrows, respectively. Residues Ser(S)16, Tyr(Y)23 and Trp(W)34 in the WW domain are critical for phospho-protein binding, while residues Lys(K)63, Ser(S)67, 
Arg(R)68/69 and Cys(C)113 contribute to the PPIase activity. Adapted from thesis: Identification and characterization of PIN1 binding partners, HKU 2010.
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mice are positively correlated with PIN1 expression 
levels. Similarly, PIN1 depletion in human HCC cells 
results in the suppression of cell proliferation, reduction 
of colony formation in soft agar and abrogation of 
tumour development in nude mice. Thus, PIN1 plays a 
critical role in hepatocarcinogenesis and the pathways 
involved are further discussed in the following sections 
(Figure 2).
PIN1 AND β-CATENIN/CYCLIN D1 
SIGNALLING PATHWAY
Dysregulation of the β-catenin signalling pathway 
resulting from β-catenin gene mutations contributes 
to HCC development. Activation of the β-catenin 
signalling pathway results in nuclear translocation 
of β-catenin protein that in turn activates the 
transcription of its target genes, including cyclin D1 
and c-Myc[59-62]. Up­regulation of cyclin D1 and c­Myc 
leads to uncontrolled cell proliferation, malignant 
transformation and tumour development. In addition 
to β-catenin gene mutations, PIN1 overexpression has 
been shown to increase the β-catenin transcriptional 
activity towards its target genes, such as cyclin D1, 
c-Myc, PPAR-δ and fibronectin[18]. The mechanism of 
PIN1 regulating β-catenin transcriptional activity is 
dependent on the direct interaction between PIN1 
and the phosphorylated Thr246-Pro motif of β-catenin. 
Such interaction stabilizes β-catenin by inhibiting its 
binding with the adenomatous polyposis coli protein 
for nuclear export and subsequent glycogen synthase 
kinase-3β-mediated degradation of β-catenin. 
This leads to increased nuclear accumulation and 
transcriptional activity of β-catenin. We have previously 
demonstrated that overexpression of PIN1 in HCC 
is associated with β-catenin accumulation[47]. More 
importantly, PIN1 overexpression and β-catenin gene 
mutations are found to be mutually exclusive events, 
further underscoring the role of PIN1 overexpression 
in causing β-catenin accumulation in HCC. Therefore, 
in addition to the somatic mutations of β-catenin that 
occur only in 20% of HCCs[63,64], PIN1 overexpression 
is the major mechanism leading to β-catenin 
accumulation in HCC.
In addition to β-catenin, PIN1 also binds other 
transcription factors to increase their transactivation 
activity towards the cyclin D1 gene. In response to 
activated c-Jun N-terminal kinases or oncogenic Ras, 
PIN1 interacts with c-Jun via its phosphorylated Ser63/
73-Pro motif and increases the transcriptional activity 
of c-Jun on its target genes, such as cyclin D1[20]. PIN1 
binds the phosphorylated Thr254-Pro motif in the p65/
RelA subunit of NF-κB[23]. This interaction stabilizes NF-
κB by inhibiting its interaction with its inhibitor IκB to 
prevent the nuclear export and subsequent ubiquitin-
mediated degradation of NF-κB. Moreover, PIN1 
increases NF-κB transactivation activity by promoting 
phosphorylation of NF-κB at Ser276 residue[52]. The 
have also been shown to inhibit PIN1 function by 
phosphorylation at Ser16[13,44,45].
PIN1 OVEREXPRESSION IN HCC
As PIN1 regulates cellular signalling, PIN1 over-
expression typically results in uncontrolled cell 
proliferation and tumour formation. A relationship 
between PIN1 and cancer was first demonstrated in 
breast cancer, in which PIN1 level positively correlated 
with tumour grade[20]. Moreover, PIN1 overexpression 
has been found in different cancers, including brain, 
breast, cervical, colon, lung and prostate[26,46].
Consistently, several studies have confirmed that 
PIN1 mRNA and protein are over-expressed in HCC 
tumours, as compared with those of the adjacent non-
tumourous liver tissues[47-50]. In one of the earliest 
studies, PIN1 overexpression was found in more than 
50% of HCC samples[47]. In addition, a study from our 
group has also demonstrated that PIN1 overexpression 
is more frequently observed in HBV-related HCCs[51]. 
Shinoda et al[52] has studied the association between 
PIN1 expression and clinicopathological characteristics 
in HCC. HCC tumours with higher PIN1 expression 
show significantly larger tumour size and higher 
frequency of portal vein invasion. Moreover, higher 
PIN1 expression is also significantly associated with 
poorer prognosis, lower overall survival and higher 
early recurrence rate (within 3 years) in patients with 
HCC. Thus, dysregulation of PIN1 expression is closely 
associated with HCC progression.
ROLES OF PIN1 IN 
HEPATOCARCINOGENESIS
Through catalysing isomerization of signalling 
molecules, PIN1 functions as a critical catalyst in 
many signalling pathways in cancer. The oncogenic 
property of PIN1 was first demonstrated in breast 
cancer, as PIN1 can transform breast epithelial cells 
through up-regulation of cyclin D1[27]. Several studies 
have demonstrated that PIN1 expression is positively 
correlated with cyclin D1 expression in various types 
of cancer[20,47,53-56]. A positive correlation has also been 
shown between PIN1 expression and centrosome 
amplification in breast cancer. Both in vitro and in 
vivo studies have demonstrated that PIN1 induces 
centrosome duplication, resulting in chromosomes 
mis-segregation and genomic instability, which in turn 
promote cell transformation and tumour growth in 
transgenic mice[57].
In hepatocytes, overexpression of PIN1 has 
been shown to promote malignant transformation. 
PIN1 overexpression in the immortalized but non-
tumourigenic liver cell line MIHA leads to anchorage-
independent colony formation in soft agar and tumour 
formation in nude mice in vivo[58]. The number of 
colonies in soft agar and the size of tumours in nude 
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PIN1-induced nuclear accumulation and activation 
of NF-κB result in increased cyclin D1 expression. 
Interestingly, PIN1 has also been shown to interact 
directly with cyclin D1 itself via its phosphorylated 
Thr286-Pro motif, resulting in protein stabilization and 
nuclear accumulation of cyclin D1[17].
PIN1 and HBx
Chronic infection with HBV is a major cause of 
HCC[65,66]. HBV is a DNA virus that facilitates malignant 
transformation by integration into the host genome 
to induce chromosome instability[67,68] and to alter 
the expression of cancer-related genes by insertional 
mutagenesis[69]. In addition, HBV modulates cell 
proliferation through the expression of viral proteins, 
in particular, the hepatitis B virus X protein (HBx)[70]. 
HBx is a gene transactivator that contributes to 
hepatocarcinogenesis through up-regulation of the 
proto-oncogenes such as c-myc, c-jun and NF-κB[71-73]. 
Studies have also shown that HBx interacts with p53 to 
inhibit the translocation of p53 into nucleus, resulting 
in the inhibition of p53-mediated cellular apoptosis 
and the development of liver tumour in transgenic 
mouse[74].
PIN1 overexpression is more frequently observed 
in HBV-related HCCs. Moreover, PIN1 directly binds 
to the phosphorylated Ser41-Pro motif in HBx[51]. This 
interaction results in the stabilization of HBx protein, 
leading to augmentation of its transactivating activity 
on the downstream target genes Bcl-XL, c-myc, and 
NF-κB[51]. Overexpression of both PIN1 and HBx leads 
to synergistic increase in cell proliferation in vitro 
Figure 2  PIN1 dysregulation and targets in hepatocellular carcinoma. PIN1 functions as an amplifier to augment the oncogenic activities of key phosphoproteins 
involved in HCC tumourigenesis. PIN1 gene expression is up-regulated by various transcription factors, including E2F family and activated NOTCH1 intracellular 
domain (NCID), but is down-regulated by miRNAs (miR-200b/c and miR-296). In addition, PIN1 inactivates retinoblastoma protein (Rb), resulting in the release of E2F 
for activation of PIN1 expression. Through phosphorylation-dependent prolyl isomerization, PIN1 activates the β-catenin/cyclin D1 signalling pathway by induction 
of β-catenin transcriptional activity and stabilization of cyclin D1 protein. In parallel, PIN1 increases the transcriptional activities of c-Jun and NF-κB, leading to an 
increase in cyclin D1 transcription. Furthermore, PIN1 stabilizes hepatitis B virus X protein (HBx) and enhances its transactivating activity on downstream target 
nuclear factor-kappa B (NF-κB), which in turn increases cyclin D1 transcription. Up-regulation of cyclin D1 leads to uncontrolled cell proliferation and tumourigenesis. 
In addition, PIN1 increases the antiapoptotic function of survivin to inhibit apoptosis and contribute to tumourigenesis. Through interaction with Akt and ribosomal S6 
kinase (p70S6K), PIN1 also activates the PI3K/Akt/mTOR pathway to promote tumourigenesis. PIN1 enhances the transcriptional activities of hypoxia-inducible factor 
(HIF)-1α and activator protein (AP)-1, resulting in up-regulation of angiogenic factor vascular endothelial growth factor (VEGF) and promotion of angiogenesis.
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and tumour growth in vivo, as compared with cells 
overexpressing PIN1 or HBx alone. These synergistic 
effects were totally dependent on the interaction 
between PIN1 and HBx. Neither the expression of the 
non-PIN1-binding HBx mutants nor PIN1 mutants that 
are defective for protein binding or isomerase activity 
cause any synergistic increase in cell proliferation and 
tumour growth.
PIN1 and survivin
In addition to the dysregulation of cell proliferation, 
the tightly regulated programmed cell death (cellular 
apoptosis) is frequently impaired in cancers. PIN1 has 
also been found to affect cellular apoptosis in breast, 
prostate and cervical cancer cells[56,75,76]. A recent 
study by our group has demonstrated an interaction 
between PIN1 and phosphorylated Thr34-Pro motif of 
survivin, an inhibitor of apoptosis protein (IAP), in HCC 
cells[48]. The function of survivin is to inhibit apoptosis 
by facilitating its interaction with hepatitis B X-interac-
ting protein (HBXIP) and pro-caspase-9, thereby 
blocking caspase-9 activation[77,78]. The antiapoptotic 
function of survivin is critical in a number of cancers, 
including HCC[79]. In our study, we showed that PIN1 
overexpression increases the binding between survivin 
and pro-caspase-9 via HBXIP, leading to suppression of 
caspase-9 and caspase-3-dependent apoptosis in HCC 
cells. Moreover, PIN1 promotes HCC tumour growth 
through inhibition of apoptosis and PIN1 expression is 
positively correlated with survivin expression in HCC 
tumours. Therefore, PIN1 enhances the antiapoptotic 
function of survivin and plays an important role in 
hepatocarcinogenesis through inhibition of apoptosis.
PIN1 and phosphoinositide 3-kinase/serine/threonine-
specific protein kinase B (Akt)/mammalian target of 
rapamycin pathway
In addition to the β-catenin signalling pathway, the 
phosphoinositide 3-kinase (PI3K)/Akt/mammalian 
target of rapamycin (mTOR) pathway is another 
important oncogenic pathway involved in HCC. 
Activation of this pathway is triggered by binding 
of multiple growth factors, including insulin and 
cytokines, to their respective cell surface receptors. 
This leads to the activation of PI3K and its subsequent 
downstream targets, including Akt, mTOR, translation 
initiation factor 4E-binding protein (4E-BP1) and 
ribosomal S6 kinase (p70S6K). Both 4E-BP1 and 
p70S6K regulate the translation of cell cycle regulatory 
proteins, and therefore, aberrant activation of the 
PI3K/Akt/mTOR pathway results in dysregulated cell 
cycle progression and tumourigenesis. It has been 
reported that mTOR phosphorylation is found in 15% 
of HCCs and total p70S6K expression is up-regulated 
in 45% of HCCs[80]. The occurrence of multiple serine 
and threonine phosphorylation events in this pathway 
suggests that PIN1 may be involved in and contribute 
to the development of HCC. Recently, PIN1 has been 
found to interact with the phosphorylated Thr92/450-
Pro motifs of Akt, resulting in the stabilization of both 
total and activated Akt (phosphorylated Ser473)[81]. 
Moreover, PIN1 expression is positively correlated 
with Akt activation in various types of human tumours 
including breast, nasopharynx and salivary gland[81]. 
Therefore, the PIN1-mediated Akt stabilization may be 
closely associated with tumourigenesis.
In addition, Lee et al[44] revealed that PIN1 interacts 
with p70S6K and facilitates the insulin-induced pho-
sphorylation of p70S6K as well as of its downstream 
target extracellular signal-regulated protein kinase 
(ERK)1/2 in human HCC cells. Through p70S6K-ERK 
signalling, co-expression of PIN1 and p70S6K leads 
to a synergistic increase in transcriptional activity of 
activator protein (AP)-1, as compared with expression 
of PIN1 or p70S6K alone[44]. The transcription factor 
AP-1 regulates gene expression through the formation 
of heterodimeric protein with other DNA binding 
proteins, such as c-Fos and c-Jun[82]. Activation of 
AP-1 regulates various cellular processes, such as cell 
proliferation, apoptosis and transformation, through 
activation of genes that encode the cell cycle regulatory 
proteins including cyclin D1, p53 and p21. Therefore, 
enforced expression of PIN1 enhances the insulin-
induced neoplastic cell transformation, whereas the 
mTOR inhibitor rapamycin that blocks the activation 
of p70S6K suppresses PIN1-induced neoplastic cell 
transformation[44]. Hence, the PIN1-p70S6K signalling 
pathway enhances AP-1 activity and mediates the 
insulin-induced neoplastic cell transformation. Thus, 
PIN1 promotes hepatocarcinogenesis partly through 
the activation of the PI3K/Akt/mTOR pathway.
PIN1 and NOTCH1
NOTCH1 signalling pathway plays a critical role in 
oncogenesis through the regulation of cell proliferation, 
differentiation and apoptosis. Ligand (γ-secretase)-
induced cleavage of the membrane-bound NOTCH1 
receptor releases its intracellular domain. This 
intracellular domain of NOTCH1 translocates into the 
nucleus and then activates the expression of target 
genes, including oncogenes c-Myc and HES1. Hence, 
activation of NOTCH1 signalling has been implicated 
in tumourigenesis. With immunohistochemistry and 
immunoblotting, NOTCH1 overexpression was found 
in 60% of HCCs[83]. In addition, enforced expression of 
the activated NOTCH1 intracellular domain completely 
rescues the inhibitory effect of γ-secretase inhibitor 
(GSI) on the cell proliferation of HCC cells[84]. As 
mentioned above, interaction between PIN1 and 
NOTCH1 stimulates the NOTCH1 signalling by relea-
sing the activated NOTCH1 intracellular domain[31]. 
Therefore, PIN1 overexpression increases the trans-
criptional activity of activated NOTCH1 intracellular 
domain and enhances the colony formation in vitro. 
Likewise, down-regulation of PIN1 decreases NOTCH1 
transcriptional activity, which in turn abrogates tumour 
Cheng CW et al . PIN1 in hepatocellular carcinoma
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growth in vivo[31]. Taken together, both in vitro and in 
vivo studies demonstrate that activation of NOTCH1 
signalling by PIN1 may potentially contribute to 
hepatocarcinogenesis.
PIN1 and angiogenesis
Angiogenesis is the formation of new blood vessels 
that enhances the development and progression of 
tumours. HCC is a highly aggressive vascular tumour 
that relies on active angiogenesis. Tumour angiogenesis 
is mainly regulated by the expression of an angiogenic 
factor, vascular endothelial growth factor (VEGF). 
VEGF functions to stimulate vascular permeability and 
subsequently promotes tumour angiogenesis[85,86]. Its 
expression is positively correlated with the angiogenic 
activity or tumour progression in HCCs[87-91]. Recently, 
PIN1 has been found to interact with hypoxia-inducible 
factor (HIF)-1α under hypoxic conditions[92,93]. HIF-
1α is an important transcription factor for VEGF gene 
expression. Down-regulation of PIN1 or suppression 
of PIN1 activity reduces the protein stability of HIF-
1α under hypoxic conditions, resulting in decreased 
transcriptional activity of HIF-1α, down-regulation 
of VEGF expression and inhibition of angiogenesis in 
vivo[92]. In addition, PIN1 overexpression has been 
found to increase the transcriptional activity of AP-1 
and the protein level of VEGF in breast cancer cells[94]. 
The transcriptional activity of AP-1 is regulated through 
the formation of heterodimer with c-Fos and c-Jun[82]. 
Since PIN1 binds c-Fos and c-Jun, and increases 
their transcription activity[20,95], it also enhances the 
transactivation activity of AP-1 (c-Jun/c-Fos dimer), 
leading to increased VEGF gene transcription. Therefore, 
PIN1 may facilitate VEGF-mediated angiogenesis of 
HCCs through the regulation of AP-1 activity.
ROLES OF PIN1 IN TUMOUR 
INVASIVENESS
Several studies have reported that PIN1 is involved 
in cell motility and contributes to cancer cell inva-
siveness. PIN1 overexpression promotes migration 
of immortalized human breast epithelial cells and 
induces epithelial-mesenchymal transition (EMT) with 
up-regulation of the mesenchymal markers including 
N-cadherin, Zeb1 and vimentin, and down-regulation 
of the epithelial marker E-cadherin[37]. Moreover, the 
protein binding WW domain and catalytic isomerization 
PPIase domain of PIN1 are essential for the induction 
of EMT in breast cancer cells. Consistently, PIN1 
silencing suppresses protein expression and promoter 
activity of EMT regulator SNAIL, leading to increased 
expression of its downstream effector E-cadherin in 
tamoxifen-resistant breast cancer cells[96]. In epidermal 
growth factor receptor (EGFR) Thr790Met mutant lung 
cancer tissues, PIN1 expression is also positively 
correlated with the mesenchymal markers vimentin 
and Zeb1[97]. PIN1 expression enhances the survival of 
EGFR-mutant lung adenocarcinoma cells with an EMT 
phenotype. In prostate cancer, PIN1 induces cellular 
migration and invasion by interacting with Smad2/3[98], 
while PIN1 depletion by siRNA inhibited migration, 
invasion and wound healing ability[75]. In addition to 
EMT, PIN1 also regulates focal adhesion kinase (FAK), 
which is a critical focal adhesion component for cell-
cell interaction and migration. By binding to protein 
tyrosine phosphatase (PTP)-PEST, PIN1-induced iso-
merization enhances the interaction of PTP-PEST with 
FAK and dephosphorylates FAK at the Tyr397 site[99]. 
Dephosphorylation of FAK promotes migration, invasion 
and metastasis of Ras-induced transformed cells. 
In conclusion, PIN1 enhances cancer cell motility by 
controlling the EMT regulating proteins expression as 
well as focal adhesion protein activity.
PIN1 AS A NEW DRUG TARGET FOR 
HCC TREATMENT
The oncogenic role of PIN1 makes it an attractive 
target for the development of anticancer drugs. Most 
of the PIN1 inhibitors developed are small molecules 
that inhibit its isomerase activity by binding to its 
catalytic active site[100] (Table 1). The first described 
PIN1 inhibitor is Juglone, which irreversibly inhibits 
the PIN1 PPIase activity[101]. Juglone was found to 
suppress tumourigenicity in human cancer cells by 
inducing apoptosis[102] and reducing number and size 
of colonies in human HCC cells in soft agar assay[44]. 
However, in addition to its PIN1-inhibitory activity, 
Juglone also directly inhibits RNA polymerase II[103], 
rendering it not suitable for clinical treatment of human 
cancers. Tatara et al[104] and Uchida et al[105] have also 
screened for additional PIN1 PPIase inhibitors using a 
chemical compound library. PiB and dipentamethylene 
thiuram monosulfide (DTM) were identified to exhibit 
specific inhibitory activity toward PPIase through 
binding to the active site of PIN1. Both PiB and DTM 
inhibit proliferation of colon carcinoma HCT116 cells by 
delaying or blocking cell cycle progression. Moreover, 
the same concentration of PiB inhibits proliferation of 
wild­type mouse embryonic fibroblasts (MEFs), but not 
Pin1-null MEFs, suggesting that PiB is more specific in 
suppression of cell proliferation through inhibition of 
PIN1. Recently, all-trans retinoic acid was also found to 
inhibit PIN1 activity and to suppress cell proliferation in 
breast cancer and acute promyelocytic leukaemia[106]. 
However, the specificity of those PIN1 inhibitors 
remains a concern as some of them also possess 
parvulin-type PPIases inhibitory activity[100]. In addition 
to directly inhibiting PIN1 activity, miRNA-mediated 
gene silencing may also be used to knock-down PIN1 
expression in cancer cells. The first miRNA mimic 
MRX34 has already been tested in phase I clinical trial 
for HCC[107]. PIN1 silencing by miR-200b/c or miR-296-
5p may provide a new approach for HCC treatment.
The application of PIN1 inhibitors or miRNAs in the 
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treatment of human cancers may be challenged by the 
fact that PIN1 is also expressed in normal cells for the 
regulation of cell division. PIN1 interacts with p53 to 
enhance protein stability and transactivation activity 
of p53 to promote cellular apoptosis in response to 
DNA damage[16,24,108]. Depletion of PIN1 has also been 
reported to induce transformation and tumourigenesis 
of MEFs through stabilization of oncogenic proteins 
Myc and cyclin E[21,22]. Therefore, it remains uncertain 
whether PIN1 inhibitors would have any adverse effect 
on normal tissues. To minimize the detrimental effects 
of PIN1 inhibitors on normal cells, a targeted delivery 
system may be employed to ensure specific drug 
delivery to HCC cells. More importantly, preclinical or 
clinical studies are necessary to examine the safety 
and effectiveness of the PIN1 inhibitors in cancer 
treatment.
Sorafenib is the only approved small molecular 
targeting agent for the treatment of advanced stage 
HCC. It is a multi-kinase inhibitor that blocks the 
Raf/Mek/Erk signalling pathway and inhibits several 
receptor tyrosine kinases, including VEGF receptor 
2 and 3. In clinical studies, patients who received 
sorafenib had longer overall survival and time to 
progression[109,110]. Recently, in vitro and in vivo studies 
have provided further evidence of the efficacy of 
sorafenib in suppressing the growth of HCC cells[111,112]. 
Through inhibition of Raf/Mek/Erk signalling, sorafenib 
suppresses proliferation and enhances apoptosis of 
HCC cells. Moreover, sorafenib inhibits the angiogenesis 
and growth of patient-derived HCC tumour xenografts 
in mice. Sorafenib has also been shown to block the 
Erk-mediated phosphorylation of Mcl-1, which is 
required for interaction with PIN1 and subsequent 
protein stabilization[76]. Indeed, sorafenib also 
inhibits the phosphorylation of another PIN1 target, 
p70S6K, which induces cell transformation through 
enforced PIN1 expression. Therefore, inhibition of 
the phosphorylation of oncogenic PIN1 interacting 
partners may be an effective treatment strategy for 
PIN1-overexpressing tumours. Furthermore, protea-
some inhibitor bortezomib (BZB) has been shown to 
suppress HCC cell growth through down-regulation of 
PIN1 and its transcription factor E2F[113]. As a single 
agent, however, the benefit of BZB in advanced 
HCC patients is limited[114]. Combination of BZB with 
other agents as treatment for HCC should be further 
evaluated.
CONCLUSION
HCC is an aggressive cancer associated with a poor 
prognosis. Conventional treatment options available for 
advanced HCC patients are very limited. Identification 
of important molecular targets in HCC may lead to 
the development of a new therapeutic approach. 
Dysregulation of PIN1 expression is associated with 
HCC and its expression is positively correlated with 
tumour size. Through phosphorylation-dependent 
prolyl isomerization, PIN1 functions as an amplifier 
to augment the oncogenic activities of its interac-
ting proteins in hepatocarcinogenesis. The diverse 
oncogenic effects exerted by PIN1 overexpression in 
HCC render PIN1 as an attractive therapeutic target 
for treatment. In fact, several studies have already 
demonstrated that inhibiting PIN1 activity results in the 
suppression of cell growth and tumour development. 
Further studies and clinical trials are required to 
examine the safety and efficacy of PIN1 inhibition in 
the treatment of HCC.
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